Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Chemotherapy Adjuvant Cisplatin/administration & dosage *Cystectomy/methods Evidence-Based Medicine Humans *Lymph Node Excision Neoadjuvant Therapy/*methods Neoplasm Invasiveness Organ Sparing Treatments/methods Randomized Controlled Trials as Topic Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/mortality/*pathology/*therapy adjuvant chemotherapy bladder cancer bladder-sparing therapy lymph node dissection neoadjuvant chemotherapy radical cystectomy

*Cytodiagnosis Female Humans Male Predictive Value of Tests Urinary Bladder Neoplasms/pathology/*urine

Meta-Analysis as Topic Polymorphism Genetic oxoguanine glycosylase 1 human [Supplementary Concept]

Diet Exercise Female Humans Male Meta-Analysis as Topic Occupational Exposure/adverse effects Occupations Risk Factors Smoking/adverse effects Urinary Bladder Neoplasms/*etiology/prevention & control Bladder cancer Lifestyle Obesity Occupation Prevention Smoking

Aminolevulinate and transurethral resection bladder cancer fluorescence hexaminolevulinate photodynamic diagnosis progression

Adult *Amino Acid Substitution Case-Control Studies DNA-Binding Proteins/*genetics Female Gene Expression *Genetic Predisposition to Disease Humans Male Middle Aged Odds Ratio *Polymorphism Single Nucleotide Risk Factors Smoking/physiopathology Tobacco Use/physiopathology Urinary Bladder Neoplasms/diagnosis/*genetics/pathology

Cross-Sectional Studies Humans Iran/epidemiology Opium/*adverse effects Risk Factors Smoking/adverse effects Substance-Related Disorders/*epidemiology/physiopathology Urinary Bladder Neoplasms/chemically induced/*epidemiology/physiopathology

*Aminolevulinic Acid Cystectomy/methods Disease-Free Survival Humans Neoplasm Recurrence Local *Photosensitizing Agents Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/diagnostic imaging/*surgery 5-aminolevulinic acid non-muscle invasive bladder cancer photodynamic diagnosis recurrence-free survival transurethral resection

Disease Progression Humans Prognosis Risk Factors Tumor Suppressor Protein p53/*metabolism Urinary Bladder Neoplasms/*metabolism/*pathology Meta-analysis Non-muscle invasive bladder cancer Progression Stage T1 p53

Humans Odds Ratio Pesticides/*adverse effects Risk Urinary Bladder Neoplasms/*chemically induced/epidemiology bladder cancer epidemiology meta-analysis pesticide exposure

androgen receptor bladder cancer meta-analysis prognosis

Critical Pathways Cystectomy/*methods/rehabilitation Humans Length of Stay Postoperative Care/*methods Postoperative Complications/*epidemiology *Standard of Care Urinary Bladder Neoplasms/*surgery Urinary Diversion/*methods/rehabilitation Clinical pathways Collaborative care Cystectomy Enhanced recovery Fast track including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Kaplan-Meier Estimate Neoplasm Grading Neoplasm Metastasis Neoplasm Staging Odds Ratio Prognosis Publication Bias Urinary Bladder Neoplasms/*mortality/*pathology/therapy histological variants squamous differentiation urothelial carcinoma of the bladder including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Adult Aged Aged 80 and over Female *Fluorodeoxyglucose F18 Humans Lymphatic Metastasis Male Middle Aged Neoplasm Staging *Positron Emission Tomography Computed Tomography *Radiopharmaceuticals Reproducibility of Results Retrospective Studies Urinary Bladder Neoplasms/*drug therapy/*pathology Bladder cancer Lymph nodes Positron emission tomography Preoperative staging Urinary bladder neoplasms

Carcinoma Transitional Cell/pathology/*surgery Electrocoagulation/*methods Humans Length of Stay Muscle Smooth/pathology Neoplasm Invasiveness *Neoplasm Recurrence Local Operative Time Prospective Studies Retrospective Studies Urinary Bladder/pathology/*surgery Urinary Bladder Neoplasms/pathology/*surgery

BCG Vaccine/*adverse effects/immunology/therapeutic use C-Reactive Protein/analysis Cancer Vaccines/*adverse effects/immunology/therapeutic use Databases Factual Dysuria/etiology Humans Lymphadenopathy/etiology Pneumonia/etiology Skin Ulcer/etiology Tuberculosis Vaccines/*adverse effects/immunology Urinary Bladder Neoplasms/*therapy

Biomarkers Tumor/genetics DNA Methylation Epigenesis Genetic *Gene Expression Regulation Neoplastic Humans Prognosis Retrospective Studies Urinary Bladder Neoplasms/*genetics Chromatin remodeling Methylation Non-coding RNA Progression Recurrence Urothelial carcinoma

Administration Intravesical Antineoplastic Combined Chemotherapy Protocols/*administration & dosage Carcinoma Transitional Cell/mortality/*pathology/*therapy Disease Progression Doxorubicin/administration & dosage/analogs & derivatives Epirubicin/administration & dosage Humans Mitomycin/administration & dosage Neoplasm Recurrence Local/*prevention & control Neoplasm Staging Randomized Controlled Trials as Topic Risk Factors Survival Rate Thiotepa/administration & dosage Time Factors Urinary Bladder Neoplasms/mortality/*pathology/*therapy Chemotherapy Meta-analysis Non–muscle-invasive bladder cancer Single instillation Systematic review

biomarker diagnosis meta-analysis microRNA muscle-invasive bladder cancer

Administration Intravesical Antineoplastic Agents/administration & dosage/*therapeutic use BCG Vaccine/administration & dosage/*therapeutic use Humans Treatment Outcome Urinary Bladder Neoplasms/*drug therapy